REG - C4X Discovery - Result of General Meeting

C4X Discovery HoldingsAnnouncement

15/04/2024 12:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240415:nRSO6593Ka&default-theme=true

RNS Number : 6593K  C4X Discovery Holdings PLC  15 April 2024

 

 

C4X Discovery Holdings plc

 

("C4XD", "C4X Discovery" or the "Company")

 

Result of General Meeting

 

15 April 2024 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug
Discovery company, announces that at the Company's General Meeting held
earlier today all resolutions were duly passed.

 

Accordingly, pursuant to the passing of Resolution 1, cancellation of
admission of the Company's ordinary shares to trading on AIM will become
effective at 7.00 a.m. on 26 April 2024.

 

In accordance with the passing of Resolution 2, the Company will re-register
as a private limited company with the name C4X Discovery Holdings Limited and
adopt new articles of association, which is expected to take place in the week
commencing 29 April 2024.

 

The results of the proxy votes received ahead of the meeting are outlined in
the table below:

 

 Resolution  Votes For                         Votes Against                     Vote Withheld  Total Votes Cast (excluding Withheld)
             No. of shares  % of shares voted  No. of shares  % of shares voted  No. of shares
 1           171,600,106    93.07%             12,787,116     6.93%              10,967,843     184,387,222
 2           171,694,784    93.12%             12,689,256     6.88%              10,971,025     184,384,040

 

Shareholders are reminded that the last day of dealings in C4X Discovery's
ordinary shares on AIM will be 25 April 2024.

 

With effect from the cancellation of admission of the Company's ordinary
shares to trading on AIM, the Company intends to implement a matched bargain
facility and has appointed Asset Match  (www.assetmatch.com) to facilitate
trading in the Ordinary Shares. This facility will allow Shareholders and new
investors to trade Ordinary Shares by matching buyers and sellers through
periodic auctions. Full details will be made available to shareholders on the
Company's website at www.c4xdiscovery.com and directly by letter or e-mail
(where appropriate).

 

From the date of cancellation, shareholder will be able to request Company
news alerts via email on the C4XD website.

 

Further details regarding the cancellation and re-registration are set out in
the circular sent to shareholders dated 27 March 2024. A copy of the circular
is available on the Company's website www.c4xdiscovery.com
(http://www.c4xdiscovery.com) .

 

- Ends -

 

Contacts

 

 C4X Discovery Holdings
 Mo Noonan, Communications                                 +44 (0)787 6444977

 Panmure Gordon (UK) Limited (NOMAD and Broker)
 Freddy Crossley, Emma Earl (Corporate Finance)            +44 (0)20 7886 2500
 Rupert Dearden (Corporate Broking)

 C4X Discovery Media - Consilium Strategic Communications
 Mary-Jane Elliott, Chris Gardner                          +44 (0)203 709 5700

 

Notes to Editors:

 

About C4X Discovery

C4X Discovery (C4XD) is a pioneering Drug Discovery company, combining
scientific expertise with cutting-edge technologies to efficiently deliver
world‑leading medicines. We have a highly valuable and differentiated
approach to Drug Discovery through our enhanced molecular design and patient
stratification capabilities, generating small molecule drug candidates across
multiple disease indications focused on immuno-inflammation. We are advancing
our internal portfolio which ranges from early-stage target opportunities to
late-stage Drug Discovery programmes and we have two commercially partnered
programmes with Sanofi and AstraZeneca, and one clinical stage candidate which
has been acquired by Indivior.

 

For more information visit us at www.c4xdiscovery.com
(http://www.c4xdiscovery.com) or follow us on twitter @C4XDiscovery.

 

 

 

EXPECTED TIMETABLE OF PRINCIPAL EVENTS

 

 Event                                                                       Time and/or date((1)(2))

 Announcement of proposed Cancellation, Re-registration and adoption of New  27 March 2024
 Articles

 Publication and posting of the Circular and the Form of Proxy               27 March 2024

 Latest time for receipt of proxy appointments in respect of the General     11.00 a.m. on 11 April 2024
 Meeting

 General Meeting                                                             11.00 a.m. on 15 April 2024

 Announcement of result of General Meeting                                   15 April 2024

 Last day of dealings in Ordinary Shares on AIM                              25 April 2024

 Cancellation                                                                7.00 a.m. on 26 April 2024

 Commencement of Matched Bargain Facility                                    26 April 2024

 Expected re-registration as a private company                               week commencing 29 April 2024

 

Notes:

 

(1)        All of the times referred to in this announcement refer to
London time, unless otherwise stated.

(2)        The timetable above assumes that the Resolutions set out in
the Notice of General Meeting are passed. Events listed in the above timetable
following the General Meeting are conditional on the Resolutions being passed
at the General Meeting without amendment.

(3)        Each of the times and dates in the above timetable is
subject to change. If any of the above times and/or dates change, the revised
times and dates will be notified to Shareholders by an announcement through a
Regulatory Information Service.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGGPUMWCUPCGGA